BOSTON and NASHUA, N.H., June 28 /PRNewswire-FirstCall/ -- Beth Israel Deaconess Medical Center (BIDMC) today announced that it has purchased another film-based Second Look(R) system from iCAD(R), Inc. , an industry-leading provider of Computer-Aided Detection (CAD) solutions for the early identification of cancer. The new system, which has been installed in its Brookline imaging clinic, complements the film and digital Second Look systems being used in the main Beth Israel Deaconess facility located in downtown Boston.
According to the American Cancer Society, it is estimated that nearly 5,000 new cases of female breast cancer will be diagnosed this year in Massachusetts alone and more than 900 women will die as a result of breast cancer in the bay state in 2005. Early detection of breast cancer can save lives and often permits less costly and less invasive cancer treatment options than when detected at a later stage. iCAD’s Second Look system acts very much like a second pair of eyes, assisting doctors in detecting up to 68% of actionable missed breast cancers an average of 15 months earlier than screening mammography alone.
Dr. Janet Baum, Director of Breast Imaging at Beth Israel Deaconess and Associate Professor of Radiology at Harvard Medical School, currently uses iCAD as a routine part of each mammography screening. “I am confident that our use of iCAD’s leading technology will help Beth Israel Deaconess patients benefit from a greater likelihood that breast cancer can be detected and treated at an earlier stage,” stated Baum. “With major health insurance providers referencing CAD as a ‘standard of care’ and ‘a medically necessary adjunct to mammography,’ our patients can rest assure knowing they are receiving the best in medical technology.”
“As a teaching and research hospital of Harvard Medical School, the technology offered at Beth Israel Deaconess is known for being at the forefront of technical excellence,” said W. Scott Parr, president and CEO of iCAD, Inc. “It is our hope that the availability of iCAD’s technology at Beth Israel Deaconess will translate to greater adoption of CAD screening throughout the country, ultimately increasing the incidence of early detection in breast cancer for all women.”
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School, and ranks third in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a research partner of Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit http://www.bidmc.harvard.edu.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to identify cancer and other life-threatening conditions earlier by making medical services more effective, more accessible and more affordable for patients worldwide. Recipient of Frost & Sullivan’s Growth Strategy Leadership award and repeatedly recognized as offering “The Winning Combination” of Price and Performance by MD Buyline, iCAD offers a comprehensive range of high- performance, upgradeable CAD systems for the high, mid and low volume mammography markets. As the most frequently selected CAD solution for film- based and digital breast screening, iCAD is entrusted with the task of early cancer detection by almost one thousand women’s healthcare centers worldwide. For more information, call +1 877 iCADnow or visit http://www.icadmed.com.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward- looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s other filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “anticipate,” “likely,” and similar expressions identify forward- looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
iCAD and Second Look are registered trademarks of iCAD, Inc.
iCAD, Inc.
CONTACT: Kevin McGrath of Cameron Associates, +1-212-245-4577,kevin@cameronassoc.com; or Monica Pandolfi of SHIFT Communications, +1-617-681-1235, mpandolfi@shiftcomm.com
Web site: http://www.icadmed.com//